Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
Evidence dashboardStudies since 2006Updated Jul 31, 2026

LixisenatideClinical Trials.

A source-linked view of every Lixisenatide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.

Total trials
75
Recruiting
2
Completed
58
Terminated
6
Results posted
27
Average enrollment
398
Countries
63
Highest phase
Phase 4

Largest indexed study

23,280,000 participants · NCT07188545 →

Developer / research origin

Sanofi

Evidence summary

Activity is not efficacy.

Lixisenatide appears in 75 indexed studies: 2 recruiting, 58 completed and 27 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Lixisenatide is safe or effective.

Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.

Development history

Trial timeline.

Evidence timeline

2006—2026

200620082008200820082008200820082009200920092009201020102010201120122012

Velocity

Lixisenatide studies by start year

Study start year · indexed snapshot

9752020062006: 1 trials2007: 0 trials2008: 7 trials2009: 5 trials20102010: 4 trials2011: 1 trials2012: 4 trials2013: 8 trials20142014: 9 trials2015: 3 trials2016: 7 trials2017: 3 trials20182018: 6 trials2019: 5 trials2020: 0 trials2021: 1 trials20222022: 3 trials2023: 1 trials2024: 2 trials2025: 4 trials20262026: 1 trials

Development

Trials by phase

Early Phase 10
Phase 17
Phase 28
Phase 333
Phase 419

Current studies

Recruiting or active

Completed studies

Finished records

Stopped studies

Withdrawn or terminated

Showing 6 of 58 studies

Full study index

Search Lixisenatide trials.

Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.

75 matching studies

Latest publications

Follow the paper trail.

PMID 38598572 ↗Meissner WG, Remy P, Giordana C, Maltete D, Derkinderen P, Houeto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carriere N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O; LIXIPARK Study Group. Trial of Lixisenatide in Early Parkinson's Disease. N Engl J Med. 2024 Apr 4;390(13):1176-1185. doi: 10.1056/NEJMoa2312323.Linked from NCT03439943PMID 30215735 ↗Whyte MB, Shojaee-Moradie F, Sharaf SE, Jackson NC, Fielding B, Hovorka R, Mendis J, Russell-Jones D, Umpleby AM. Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance. J Clin Endocrinol Metab. 2019 Feb 1;104(2):359-368. doi: 10.1210/jc.2018-01176.Linked from NCT02049034PMID 23882037 ↗DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013 Aug;36 Suppl 2(Suppl 2):S127-38. doi: 10.2337/dcS13-2011. No abstract available.Linked from NCT05136287PMID 8366922 ↗Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86. doi: 10.1056/NEJM199309303291401.Linked from NCT05136287PMID 9742976 ↗Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53.Linked from NCT05136287PMID 20609967 ↗Emerging Risk Factors Collaboration; Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 Jun 26;375(9733):2215-22. doi: 10.1016/S0140-6736(10)60484-9.Linked from NCT05136287PMID 19545590 ↗Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38. doi: 10.1016/j.pharmthera.2009.06.002. Epub 2009 Jun 21.Linked from NCT05136287PMID 26378978 ↗Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.Linked from NCT05136287

Related pages

Keep researching Lixisenatide.

Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.

DatabaseLixisenatide database page →Research guideRead the Lixisenatide guide →Lab reportsSearch the COA ledger →Source registrySearch ClinicalTrials.gov ↗